Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PALATIN TECHNOLOGIES, INC.

(PTN)
  Report
Delayed Nyse  -  01:54:09 2023-06-08 pm EDT
2.340 USD   +2.63%
05/31Palatin presents preclinical diabetic nephropathy data at the international podocyte conference
AQ
05/30Palatin Technologies, Inc. Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference
CI
05/17Palatin reports third quarter fiscal year 2023 financial results and provides corporate update
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/02/2023 06/05/2023 06/06/2023 06/07/2023 06/08/2023 Date
2.33(c) 2.35(c) 2.28(c) 2.28(c) 2.34 Last
32 393 39 649 18 410 48 678 53 911 Volume
+2.64% +0.86% -2.98% 0.00% +2.63% Change
More quotes
Estimated financial data (e) (USD)
Sales 2023 4,47 M - -
Net income 2023 -23,3 M - -
Net Debt 2023 - - -
P/E ratio 2023 -1,08x
Yield 2023 -
Sales 2024 9,28 M - -
Net income 2024 -27,9 M - -
Net Debt 2024 - - -
P/E ratio 2024 -1,28x
Yield 2024 -
Capitalization 26,3 M 26,3 M -
Capi. / Sales 2023 5,88x
Capi. / Sales 2024 2,83x
Nbr of Employees 33
Free-Float 85,6%
More Financials
Company
Palatin Technologies, Inc. is a biopharmaceutical company developing medicines based on molecules that modulate the activity of the melanocortin receptor (MCr) system. The CompanyÔÇÖs product candidates are targeted, receptor-specific therapeutics for the treatment of diseases. Its MCr system has effects on inflammation and immune system response, food intake, metabolism, and sexual function. The CompanyÔÇÖs... 
More about the company
Ratings of Palatin Technologies, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about PALATIN TECHNOLOGIES, INC.
05/31Palatin presents preclinical diabetic nephropathy data at the international podocyte co..
AQ
05/30Palatin Technologies, Inc. Presents Preclinical Diabetic Nephropathy Data at the Intern..
CI
05/17Palatin reports third quarter fiscal year 2023 financial results and provides corporate..
AQ
05/16Transcript : Palatin Technologies, Inc., Q3 2023 Earnings Call, May 16, 2023
CI
05/16Earnings Flash (PTN) PALATIN TECHNOLOGIES Reports Q3 Revenue $1.2M, vs. Street Est of $..
MT
05/16North American Morning Briefing: Retail Sales, -2-
DJ
05/15Palatin Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
05/12Palatin to report third quarter fiscal year 2023 results, teleconference and webcast to..
AQ
05/09Palatin Technologies Inc : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/09Palatin Technologies, Inc. Presents PL8177 Ulcerative Colitis Data at Digestive Disease..
CI
05/08Transcript : Palatin Technologies, Inc. - Special Call
CI
05/01Palatin Technologies Inc : Other Events (form 8-K)
AQ
04/28Palatin presents initial dry eye disease phase 3 clinical data at the association of re..
AQ
04/27Palatin Technologies Inc : Other Events (form 8-K)
AQ
04/26Palatin presents data at the association of research in vision and ophthalmology 2023 a..
AQ
More news
News in other languages on PALATIN TECHNOLOGIES, INC.
05/30Palatin Technologies, Inc. présente des données précliniques sur la néphropathie diabét..
05/15Palatin Technologies, Inc. annonce ses résultats pour le troisième trimestre et les neu..
05/09Palatin Technologies, Inc. présente des données sur le PL8177 dans la colite ulcéreuse ..
04/25Palatin présente à la conférence annuelle 2023 de l'Association of Research in Vision a..
02/14Palatin Technologies, Inc. annonce ses résultats pour le deuxième trimestre et le semes..
More news
Analyst Recommendations on PALATIN TECHNOLOGIES, INC.
More recommendations
ETFs positioned on PALATIN TECHNOLOGIES, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Vanguard Extended Market ETF - USD0%4.32%United_States
Vanguard Total Stock Market ETF - USD0%0.15%United_States
Vanguard Total Stock Market ETF - USD0%2.25%United_States
IShares Core MSCI All Country World ex Cana...0%2.62%-World
More ETFs positioned on PALATIN TECHNOLOGIES, INC.
Chart PALATIN TECHNOLOGIES, INC.
Duration : Period :
Palatin Technologies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PALATIN TECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 2,28 $
Average target price 43,00 $
Spread / Average Target 1 786%
EPS Revisions
Managers and Directors
Carl Spana Director
Stephen T. Wills CFO, Secretary, Treasurer & Executive VP
John K. A. Prendergast Director
Michael B. Raizman Chief Medical Officer
John Dodd Senior Vice President-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
PALATIN TECHNOLOGIES, INC.-10.94%26
VERTEX PHARMACEUTICALS INCORPORATED14.42%83 614
REGENERON PHARMACEUTICALS, INC.3.69%79 115
BIONTECH SE-27.17%26 367
WUXI APPTEC CO., LTD.-21.88%26 060
GENMAB A/S-8.53%25 225
1 MarketScreener is worth more than 1000 Influencers!
100% Free Registration
fermer